Donnatal was pulled from the U.S. market because the FDA determined it had never been formally approved through the modern drug approval process and pressured its manufacturer to stop selling it. The drug, a decades-old combination of phenobarbital and belladonna alkaloids used for gastrointestinal complaints, had been marketed since the mid-twentieth century under a regulatory gray area that allowed pre-1962 drugs to remain on pharmacy shelves without proving they actually worked. When the FDA finally closed that loophole, Donnatal’s manufacturer chose to discontinue the product rather than pursue full approval, a path that would have required expensive clinical trials for a drug with known safety concerns and limited modern evidence of efficacy.
What Donnatal Actually Was
Donnatal was a fixed-combination prescription drug containing four active ingredients: phenobarbital (a barbiturate sedative), hyoscyamine, atropine, and scopolamine. The last three are belladonna alkaloids, compounds derived from the deadly nightshade plant that work by blocking acetylcholine, a chemical messenger in the nervous system. The idea behind the combination was to slow gut motility, reduce stomach acid secretion, and ease cramping while the phenobarbital component provided mild sedation and reduced anxiety-driven symptoms. Doctors prescribed it most often for irritable bowel syndrome, peptic ulcer disease, and various functional gastrointestinal disorders.
The drug came in tablet, capsule, elixir, and extended-release forms and was manufactured for decades, most recently by Concordia Pharmaceuticals (later part of Bausch Health). For many patients, especially older adults who had taken it for years, Donnatal felt like a trusted remedy. Its discontinuation left a lot of people scrambling for answers and alternatives.
The Regulatory Gap That Let Donnatal Survive So Long
To understand why Donnatal was pulled, you need to understand a quirk in American pharmaceutical regulation. Before 1962, drugs could be sold in the United States without demonstrating that they were effective. The Kefauver-Harris Amendment changed that, requiring manufacturers to prove both safety and efficacy before marketing. But drugs already on the market were not immediately removed. Instead, the FDA launched a massive review process called the Drug Efficacy Study Implementation, or DESI, which evaluated thousands of pre-1962 drugs. Many were found to lack adequate evidence of effectiveness, but enforcement was slow and inconsistent. Some drugs, including Donnatal, continued to be sold for decades in this regulatory limbo.
By the early 2000s, the FDA estimated that hundreds of drug products were still being marketed in the United States without formal approval. In 2006, the agency launched the Unapproved Drugs Initiative, a systematic effort to either force manufacturers to obtain proper FDA approval or remove unapproved products from the market. Between 2006 and 2015, 34 previously unapproved prescription drugs were addressed through this initiative. Among the drugs that did obtain approval, nearly 90% relied on literature reviews or bioequivalence studies rather than new clinical trials.1PubMed Central. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States That detail matters because it reveals how thin the evidentiary bar actually was for many of these products, and Donnatal’s manufacturer still did not clear it.
Donnatal lingered in this unapproved status far longer than many comparable drugs. The FDA eventually sent warning letters to the manufacturer, making clear that continued marketing of Donnatal without approval was a violation of federal law. Rather than invest in the clinical trials and regulatory submissions needed for formal approval, the manufacturer ceased production. The result was that Donnatal effectively vanished from U.S. pharmacies.
Why the Manufacturer Walked Away
A reasonable question is why the company did not simply pursue FDA approval. The economics tell the story. Running modern clinical trials for a combination drug with four active ingredients, one of which is a controlled substance, would have been enormously expensive. Phenobarbital is a Schedule IV barbiturate, a class of drugs that carries significant regulatory scrutiny on its own. The belladonna alkaloids bring their own safety baggage. And the patient population for functional gastrointestinal disorders has changed substantially since Donnatal’s heyday, with many newer treatment options available.
Even if trials showed the drug worked, the manufacturer would face a difficult market reality. Physicians had been gradually moving away from prescribing Donnatal for years, partly because of safety concerns and partly because treatment guidelines for conditions like IBS had evolved. The return on investment for a successful approval was far from guaranteed. For a drug company weighing the cost of modern trials against the likely revenue of an aging product with growing competition, the math simply did not work out.
The Safety Problems Nobody Could Ignore
Donnatal’s safety profile was a significant factor in the FDA’s willingness to let the product die. The drug combined two categories of ingredients that each carry real risks, and together they raised compounding concerns.
Phenobarbital, the barbiturate component, is a central nervous system depressant with well-documented potential for physical dependence. Research on patients taking barbiturates long-term has found that roughly half develop withdrawal symptoms and tolerance, though fewer than one in ten report loss of control or craving.2PubMed Central. Low Risk of Development of Substance Dependence for Barbiturates and Clobazam Prescribed as Antiepileptic Drugs: Results from a Questionnaire Study Tolerance means patients need increasing doses to get the same effect, while withdrawal can produce anxiety, insomnia, tremors, and in severe cases, seizures. For a drug being prescribed to manage a chronic condition like IBS, the prospect of patients becoming physically dependent on their gastrointestinal medication was troubling. Phenobarbital also interacts dangerously with alcohol, opioids, and many other common medications, increasing the risk of excessive sedation or respiratory depression.
The belladonna alkaloid components, atropine, hyoscyamine, and scopolamine, are anticholinergic agents. These compounds block the neurotransmitter acetylcholine throughout the body, which is how they reduce gut spasms but also why they cause a predictable set of side effects: dry mouth, blurred vision, urinary retention, constipation, confusion, and rapid heart rate. In cases of overexposure or overdose, these alkaloids can cause a full anticholinergic toxidrome, a potentially dangerous syndrome, though not every poisoning case presents all characteristics.3American Journal of Therapeutics. Belladonna Alkaloid Intoxication: The 10-Year Experience of a Large Tertiary Care Pediatric Hospital
These anticholinergic effects were particularly concerning for two vulnerable populations: older adults and children. In elderly patients, anticholinergic drugs are associated with increased fall risk, cognitive impairment, and delirium. Multiple widely used clinical guidelines, including the Beers Criteria for potentially inappropriate medications in older adults, had already flagged anticholinergic drugs as substances to avoid in geriatric patients. For children, the narrow therapeutic window of belladonna alkaloids made dosing errors especially dangerous. The combination of a barbiturate sedative and anticholinergic agents in a single pill aimed at a chronic condition was, by modern safety standards, increasingly hard to justify.
Did Donnatal Even Work?
This is where the story gets uncomfortable for longtime users. The honest answer is that Donnatal never had strong evidence of efficacy by contemporary standards. The drug was developed and marketed in an era when clinical trial methodology was far less rigorous, and the studies that did exist were generally small, poorly controlled, and conducted decades ago. When the FDA reviewed the evidence as part of its broader assessment of unapproved drugs, Donnatal lacked the kind of modern clinical data that would satisfy current approval requirements.
That does not necessarily mean the drug did nothing. Many patients reported genuine symptom relief, and the pharmacological mechanisms are plausible: anticholinergic agents do slow gut motility and reduce spasms, and phenobarbital does reduce anxiety. But subjective symptom improvement in a condition like IBS, where the placebo response rate is notoriously high, is not the same as proven efficacy in a randomized controlled trial. The gap between “patients feel better” and “the drug demonstrably outperforms placebo in rigorous testing” is wide, and Donnatal never convincingly bridged it with modern evidence.
What the FDA’s Crackdown Meant for Other Drugs
Donnatal’s story was not unique. The Unapproved Drugs Initiative affected dozens of products, and the consequences extended beyond just availability. Among 26 drugs with available pricing data that were addressed by the initiative between 2006 and 2015, prices rose by a median of 37% in the two years surrounding voluntary approval or FDA action, with some drugs seeing increases exceeding 200%. Drug shortages also worsened: the number of affected drugs in shortage rose from half to nearly three-quarters during the same period.1PubMed Central. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States
The pattern was predictable: when the FDA required formal approval for previously unapproved drugs, manufacturers that chose to pursue it often gained market exclusivity, which allowed them to raise prices substantially. Manufacturers that chose not to pursue approval simply pulled their products, leaving patients without access. Either way, patients bore the cost, whether through higher prices or loss of a medication they depended on. Donnatal fell into the second category, disappearing entirely rather than becoming more expensive.
Modern Alternatives for IBS and Gut Spasms
If you were taking Donnatal for IBS or another gastrointestinal condition, you are not without options, and the alternatives generally have stronger evidence behind them. Antispasmodic drugs remain a mainstay treatment for IBS, with survey data indicating that roughly 30% of patients with IBS with diarrhea have used them at some point.4PubMed Central. Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options In the United States, the most commonly prescribed antispasmodic for IBS is dicyclomine (Bentyl), which targets gut smooth muscle without the barbiturate component. Hyoscyamine is also available as a standalone drug without phenobarbital, though it carries the same anticholinergic side effects.
The American Gastroenterological Association’s clinical practice guideline for IBS with diarrhea provides conditional recommendations for several treatment categories, including antispasmodics, though the certainty of evidence is rated as low. The same guideline also conditionally recommends rifaximin, eluxadoline, alosetron, loperamide, and tricyclic antidepressants, each with varying levels of supporting evidence.5Gastroenterology. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea The picture that emerges is that IBS treatment in 2024 involves a broader toolkit than what was available when Donnatal dominated the conversation, even if no single drug works perfectly for everyone.
For patients whose primary issue was cramping and spasm, dicyclomine or hyoscyamine alone often serves as a reasonable substitute. For those whose IBS involved a significant anxiety or stress component, which the phenobarbital in Donnatal was partly addressing, low-dose tricyclic antidepressants or gut-directed psychotherapy may be more appropriate and better supported by evidence. Peppermint oil capsules, while not a prescription drug, have also shown modest antispasmodic effects in clinical trials and are sometimes recommended as a first-line option for mild symptoms.
Why Some Patients Were Angry
The discontinuation of Donnatal generated real frustration among patients who had relied on it for years, sometimes decades. For some, no alternative worked as well, or at least not in the same way. Part of this is pharmacological: the specific combination of anticholinergic effects plus mild barbiturate sedation is not easily replicated by any single modern drug. Part of it is psychological: when you have taken a medication that you associate with symptom control for a long time, switching to something unfamiliar is stressful, especially when the switch was forced rather than chosen.
There was also a philosophical objection that many patients and some physicians voiced: if a drug has been on the market for half a century and has a known safety profile, why should the FDA pull it now? The counterargument, and the one the FDA ultimately acted on, is that “known safety profile” is not the same as “proven safe and effective.” Many drugs that predated modern approval standards turned out to cause more harm than good, or to be no better than placebo, when finally subjected to rigorous testing. The uncomfortable truth is that longevity on the market is not evidence of efficacy.
For patients who found themselves without Donnatal, the practical advice from gastroenterologists was generally to work with their doctor to identify which symptom, whether cramping, diarrhea, anxiety, or some combination, was most dominant and to target it with a drug that has modern evidence supporting its use for that specific symptom. That piecemeal approach may feel less elegant than a single combination pill, but it reflects how medicine has moved toward more targeted treatments with clearer benefit-risk profiles.
Compounding Pharmacies and the Gray Market
After Donnatal’s discontinuation, some patients turned to compounding pharmacies, which can legally prepare custom formulations of drugs using individual ingredients. A compounding pharmacy could theoretically combine phenobarbital, hyoscyamine, atropine, and scopolamine to recreate the Donnatal formula. This practice exists in a regulatory space that is less tightly controlled than FDA-approved manufacturing. Compounded drugs do not undergo the same quality testing, and the consistency of dosing can vary between batches and between pharmacies.
Whether a compounding pharmacy will prepare a Donnatal-equivalent formulation depends on state regulations and whether a physician is willing to write the prescription. Some doctors have continued prescribing the compounded version for patients who insist on it, while others have used the discontinuation as an opportunity to transition patients to alternatives with better evidence. If you are considering the compounded route, it is worth knowing that you are getting a product with less quality oversight than a commercially manufactured drug, and you are still getting phenobarbital, a barbiturate with dependence potential, and anticholinergic agents with their attendant side effects.
The Anticholinergic Burden Problem
One aspect of Donnatal’s discontinuation that received less attention than it deserved is the growing body of research on cumulative anticholinergic burden. When a person takes multiple medications with anticholinergic properties, the effects stack. Many common drugs have at least mild anticholinergic activity, including certain antihistamines, antidepressants, bladder medications, and sleep aids. Adding a drug like Donnatal, which contains three anticholinergic agents, to an existing medication regimen could push someone’s total anticholinergic load into a range associated with cognitive decline, particularly in people over 65.
This cumulative effect is measured using scoring systems that add up the anticholinergic potential of all a patient’s medications. Research over the past two decades has increasingly linked high anticholinergic burden scores to increased risk of dementia, falls, hospitalization, and death in older adults. Donnatal, with its triple anticholinergic payload, was a significant contributor to that burden for any patient taking it alongside other common medications. Its removal from the market, viewed through this lens, was arguably overdue for the geriatric population.
For younger patients without other anticholinergic medications, the cumulative burden argument is less pressing, but the standalone side effects of the belladonna alkaloids remain relevant: dry mouth, constipation (ironic for a gastrointestinal drug), urinary difficulty, and blurred vision are not trivial quality-of-life issues, especially for a drug taken daily over months or years.
Phenobarbital in the Twenty-First Century
Phenobarbital is still used in medicine, primarily as an anticonvulsant for epilepsy, particularly in resource-limited settings where newer and more expensive antiepileptic drugs are not available. It remains on the World Health Organization’s List of Essential Medicines. But its role has narrowed dramatically in wealthy countries, where safer alternatives with fewer drug interactions and less dependence potential have largely replaced it for seizure control.
Using phenobarbital for a functional gastrointestinal condition was, by the time Donnatal was discontinued, an anachronism. The drug was essentially being prescribed as a mild sedative for gut-related anxiety, a purpose for which modern medicine has far better tools. The fact that patients could develop physical dependence on what was nominally a stomach medication struck many pharmacologists and regulators as an unacceptable risk, especially when the efficacy of the combination had never been rigorously demonstrated. The barbiturate component was arguably the single biggest reason the FDA and clinical community were unwilling to champion Donnatal’s continued availability.